featured
Momelotinib vs Danazol in Symptomatic Patients With Anaemia and Myelofibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Lancet 2023 Jan 28;401(10373)269-280, S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, AT Kuykendall, S Grosicki, A Iurlo, YT Goh, MC Lazaroiu, M Egyed, ML Fox, D McLornan, A Perkins, SS Yoon, V Gupta, JJ Kiladjian, N Granacher, SE Lee, L Ocroteala, F Passamonti, CN Harrison, BJ Klencke, S Ro, R Donahue, J Kawashima, R MesaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.